Cargando…
Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
Currently, conventional therapies for acute myeloid leukemia (AML) have high failure and relapse rates. Thus, developing new strategies is crucial for improving the treatment of AML. With the clinical success of anti-CD19 chimeric antigen receptor (CAR) T cell therapies against B-lineage malignancie...
Autores principales: | Fan, Mingxue, Li, Minghao, Gao, Lipeng, Geng, Sicong, Wang, Jing, Wang, Yiting, Yan, Zhiqiang, Yu, Lei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576380/ https://www.ncbi.nlm.nih.gov/pubmed/28851445 http://dx.doi.org/10.1186/s13045-017-0519-7 |
Ejemplares similares
-
Chimeric antigen receptor T-cell therapy in acute myeloid leukemia
por: Koedam, Jan, et al.
Publicado: (2022) -
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
por: Hofmann, Susanne, et al.
Publicado: (2019) -
Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
por: Marvin-Peek, Jennifer, et al.
Publicado: (2022) -
Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia
por: Schorr, Christopher, et al.
Publicado: (2022) -
Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia
por: Maucher, Marius, et al.
Publicado: (2021)